Great point! I was thinking the same thing.....Management cant selectively divulge material information to select shareholders or attendees. I do think the company will stay aggressive with moving the pipeline forward and monetizing assets somewhere over the next few months (as they need to get this Up listed to attract better investment partners).
It would be great if AMBS acquired a revenue producing asset and/or merged the diagnostic divisions with an already publicly traded company as well. There are so many possibilities that exist to create shareholder value (time will tell).
(0)
(0)
Amarantus Bioscience Holdings (AMBS) Stock Research Links